Aim: The aim was to study the pattern of adverse drug reaction (ADR) provoked by anticancer therapy and to assess the quality of life (QoL) in cancer patients.
Materials And Methods: This study was conducted in Tamil Nadu on 75 patients from February to July 2019 taking into account their demographic profile, ADR occurrence and its causality, outcome, organ system-wise distribution of ADRs, and others. The causality assessment was done by using Naranjo's scale and QoL was assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) scale. The QoL was compared in any two consecutive cycles between the 2 and 5 cycles of chemotherapy.
Results: Out of the 75 patients, 17 male and 56 female patients developed ADR. A total of 228 ADRs were observed in 73 patients. The most commonly occurred ADR was nausea and vomiting (45%) and the most commonly affected system was gastrointestinal tract (37%). According to causality assessment, the ADR that occurred falls mostly in the category of probable (66.7%) followed by possible (29.3%) and the outcome of the ADR was mostly recovering (49.3%). The QoL was higher in females and in the age group of 40-49 years. The physical and emotional well-being of the patient were affected more. The overall QoL was improved in the 2 visit when compared to the 1 visit.
Conclusion: Cancer is known to cause a significant impact on the health and socioeconomics of a nation. To boost the QoL in patients, it is essential to identify and manage the ADRs by taking appropriate measures to promote judicious use of drugs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/jcrt.JCRT_1015_19 | DOI Listing |
J Transl Med
January 2025
Scientia Clinical Research and Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.
Background: A novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC) GQ1001 was assessed in patients with previously treated HER2 positive advanced solid tumors in a global multi-center phase Ia dose escalation trial.
Methods: In this phase Ia trial, a modified 3 + 3 study design was adopted during dose escalation phase. Eligible patients were enrolled, and GQ1001 monotherapy was administered intravenously every 3 weeks.
Background: Antibiomania is the manifestation of manic symptoms secondary to taking an antibiotic, which is a rare side effect. In these cases, the antibiotics most often incriminated are macrolides and quinolones, but to our knowledge, there are no published cases of antibiomania secondary to cotrimoxazole. Furthermore, we also provide an update of pharmacovigilance data concerning antibiomania through a search of the World Health Organization (WHO) database.
View Article and Find Full Text PDFLung
January 2025
National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France.
Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis (PPF), nintedanib slowed the decline in forced vital capacity (FVC) versus placebo, with a safety profile characterised mainly by gastrointestinal events. INBUILD-ON, the open-label extension of INBUILD, assessed the safety of nintedanib during longer-term treatment. Data on FVC were collected.
View Article and Find Full Text PDFWorld J Microbiol Biotechnol
January 2025
The Key Laboratory for Extreme-Environmental Microbiology, College of Plant Protection, Shenyang Agricultural University, Shenyang, 110866, China.
The endophytic fungus Serendipita indica (Si) could suppress Phoma arachidicola (Pa) and control peanut web blotch disease. The study evaluated its growth-promoting and disease-resistant effects in two peanut cultivars, Luhua11 and Baisha1016. In vitro experiments and microscopy analysis demonstrated that S.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Hepatobiliary and Pancreatic Surgery, Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Pembrolizumab plus Lenvatinib is regarded as a significant treatment option for advanced unresectable hepatocellular carcinoma (HCC). This study aims to meticulously monitor and identify adverse events (AEs) related to this combined therapy, enhance patient safety, and offer evidence-based recommendations for the appropriate use of these drugs. We gathered adverse drug reactions (ADRs)-related data from the FAERS database for HCC patients who received Pembrolizumab, both alone and in combination with Lenvatinib from the first quarter of 2014 to the fourth quarter of 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!